SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. is trending sharply higher due to news of a strategic AI licensing partnership in Africa, which includes an institution-approved mental health pilot program. The community is actively discussing a potential short squeeze, fueled by the stock's high short interest and low float, with many anticipating continued significant upward movement as it gets compared to other recent high-flying microcaps.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is generating significant discussion as investors keenly await upcoming 3-year functional results from its ELEVIDYS gene therapy's EMBARK Phase 3 trial. The community is buzzing with optimism for a potential positive outcome that could lead to a stock surge and even buyout speculation, though many are also voicing caution given the binary nature of such clinical readouts. This anticipated data for their Duchenne muscular dystrophy treatment is a major catalyst shaping sentiment around the company's valuation and future.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is experiencing heightened volatility and community debate amid a widespread service outage affecting its core Microsoft 365 products. This is unfolding as Wall Street analysts trim price targets due to broader sector valuation concerns, even while maintaining bullish long-term outlooks on Azure's AI-driven growth and recent government contracts. Investors are sharply divided between those seeing a significant buying opportunity at recent lows, eyeing potential post-earnings upside, and those expressing skepticism over AI monetization, operational stability, and overall valuation.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is experiencing significant volatility driven by recent reports of mixed sports betting revenue during the NFL playoff season, alongside intensifying competition from prediction markets. While some investors express frustration over perceived underperformance and management, others view current price levels as a buying opportunity, especially given recent legal developments against unregulated betting platforms and the approaching Super Bowl season. The sector faces ongoing regulatory scrutiny, creating considerable debate around the future competitive environment for online gambling companies.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies Inc. (QCLS) is drawing significant community attention after appointing OpenAI's Chelsea Voss to its Board of Directors, validating its pivot into quantum-class photonic computing. This development is largely seen as a major catalyst, fueling discussions about the company's legitimacy in the AI space, its potential for a substantial short squeeze, and considerable future upside.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is experiencing a historic surge, breaking key psychological barriers as silver hits $100 an ounce. This parabolic rally is driven by strong industrial demand, particularly from EVs and electronics, coupled with a weakening dollar and heightened geopolitical tensions, leading to intense speculation about a massive short squeeze. While bulls celebrate a potential generational revaluation of the metal, some market participants anticipate an unsustainable blow-off top, questioning the longevity of the rapid ascent.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG CRYPTO, or 'Infinite Money Glitch,' is trending as its community actively discusses consistent passive Solana rewards to holders based on trading volume. The project is generating buzz around new Liquidity Pools, forthcoming audit technology, and potential CEX listings. Enthusiasm stems from its proven track record of distributing earnings over nearly a year, solidifying its reputation as a resilient, long-term passive income play.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing a historic rally, nearing significant psychological price levels that have ignited intense community discussion. Many view gold's ascent as a critical safe-haven play against global economic uncertainties and dollar weakness, while a strong counter-narrative cautions against a 'mania' or 'bubble' driven by unsustainable momentum and potential market manipulation.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing a resilient rally, largely fueled by robust performance from select mega-cap tech stocks, prompting continuous dip-buying by many. This strength is occurring despite community concerns over market manipulation, low trading volume, and significant institutional selling in dark pools. Investors are also closely monitoring rising geopolitical tensions and potential domestic disruptions, adding an undercurrent of caution heading into the weekend.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is a top trending stock, with widespread community discussion centered on its potential for a significant short squeeze, highlighted by escalating borrowing fees. Investor sentiment is strongly bullish, fueled by recent positive clinical data in glioblastoma where a "median overall survival not yet reached" is signaling exceptional patient outcomes. The ongoing discourse also includes anticipation of imminent regulatory decisions for bladder cancer, global expansion initiatives, and the broader, long-term impact of its innovative oncology pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Penny Stocks To Watch Now - November 17th

Leap Therapeutics, Autonomix Medical, Cypherpunk Technologies, Annovis Bio, and Datavault AI are the five Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are...

Autonomix Medical, Inc. (AMIX) Upgraded to Strong Buy: Here's Why

Autonomix Medical, Inc. (AMIX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech

Monte Rosa Therapeutics Inc. (<a class="mention" data-mention="$GLUE" data-symbol-id="GLUE" href="https://stocktwits.com/symbol/GLUE" target="_blank">$GLUE</a>)<figure class="image"><a href="https://stocktwits.com/symbol/GLUE"><img style="aspect-ratio:1284/287;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132438_e581646ba1.png" alt="Screenshot 2024-10-28 132438.png" width="1284" height="287"></a><figcaption>Monte Rosa Therapeutic's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Monte Rosa Therapeutics surged over 130% on Monday, reaching a two-year high of $12.15 after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-enthralls-retail-with-novartis-licensing-deal/cJ2rnM9RJW">announcing an exclusive global licensing agreement with Novartis AG ($NVS).</a>&nbsp;The collaboration focuses on developing innovative treatments for immune-related conditions, particularly MRT-6160, an oral drug designed to inhibit the degradation of VAV1, a key signaling protein for T and B cell receptors.&nbsp;As part of the agreement, Novartis will pay $150 million upfront for exclusive worldwide rights to MRT-6160 and other VAV1-targeting molecular glues, with Monte Rosa eligible for up to $2.1 billion in milestones and tiered royalties on international sales.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with ‘extremely high’ (97/100) message volume.Evoke Pharma Inc. (<a class="mention" data-mention="$EVOK" data-symbol-id="EVOK" href="https://stocktwits.com/symbol/EVOK" target="_blank">$EVOK</a>)<figure class="image"><a href="https://stocktwits.com/symbol/EVOK"><img style="aspect-ratio:1282/282;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132459_473ee74b09.png" alt="Screenshot 2024-10-28 132459.png" width="1282" height="282"></a><figcaption>Evoke Pharma's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Evoke Pharma’s shares were up over 30% on Monday following its presentation of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/evoke-pharma-stock-spikes-higher-on-study-data/cJ2rllaRJO">positive data for its lead drug</a>, Gimoti, as a treatment option for diabetes gastroparesis.The company ranked among the top 10 trending stocks on Stocktwits, secured the second spot for most watched, and was listed in the top 20 most active stocks&nbsp;on Monday afternoon.Evoke Pharma and its partner, Eversana, found that patients using Gimoti, a nasal version of metoclopramide, experienced significant improvements compared to those using the oral formulation. Patients who received the nasal treatment had reduced healthcare resource use and fewer healthcare visits.Retail sentiment on Stocktwits surged into ‘extremely bullish’ territory (97/100) with ‘extremely high’ (97/100) message volume.Autonomix Medical Inc. (<a class="mention" data-mention="$AMIX" data-symbol-id="AMIX" href="https://stocktwits.com/symbol/AMIX" target="_blank">$AMIX</a>)<figure class="image"><a href="https://stocktwits.com/symbol/AMIX"><img style="aspect-ratio:1271/277;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132518_8d6392edf1.png" alt="Screenshot 2024-10-28 132518.png" width="1271" height="277"></a><figcaption>Autonomix Medical's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Autonomix skyrocketed by more than 90% on Monday morning following the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/autonomix-stock-rallies-on-strong-trial-results/cJ2rlAHRJf">announcement of positive results from its clinical trial</a> aimed at alleviating pain in pancreatic cancer patients.&nbsp;The stock became the second-highest trending on Stocktwits, just behind Trump Media &amp; Technology Group Corp. ($DJT), and was listed among the top 10 most watched stocks of the day.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with chatter escalating into ‘extremely high’ (97/100) territory.For updates and corrections email newsroom@stocktwits.com.Read more: <a href="https://stocktwits.com/news-articles/markets/equity/mstr-stock-hits-all-time-high-as-btc-crosses-68000/cJ2rj2hRJ9">MicroStrategy’s Bitcoin Holdings Drive Historic High: Retail Unfazed</a>

Retail is most bullish on these stocks today | Source: Pexels

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention

Retail sentiment was particularly strong for healthcare stocks today, as Monte Rosa, Autonomix, and Evoke Pharma each announced positive developments regarding their respective innovations.

Equity

Retail sentiment was particularly strong for healthcare stocks today, as Monte Rosa, Autonomix, and Evoke Pharma each announced positive developments regarding their respective innovations.


Shares of Autonomix Medical Inc. (<a class="mention" data-mention="$AMIX" data-symbol-id="AMIX" href="https://stocktwits.com/symbol/AMIX" target="_blank">$AMIX</a>) soared by over 90% on Monday morning after the company reported positive results from its clinical trial focused on managing pain in pancreatic cancer patients.It ranked as the second-highest trending stock on Stocktwits on Monday, trailing only Trump Media &amp; Technology Group Corp. (<a class="mention" data-mention="$DJT" data-symbol-id="DJT" href="https://stocktwits.com/symbol/DJT" target="_blank">$DJT</a>), and was also among the top 10 most watched stocks.The trial employs an innovative technique to target and ablate the nerves responsible for pain in late-stage pancreatic cancer patients.&nbsp;Early results from the first five participants, known as the "lead-in" cohort, have been promising, with all reporting significant pain relief after the procedure.Set to conclude by the end of 2024, the trial seeks to provide an alternative to opioid pain management, which poses risks of addiction and overdose.Autonomix's technology features a catheter-based microchip sensing array antenna, which can detect neural signals more sensitively than current technologies. This precision-guided approach is intended to diagnose and treat issues related to the peripheral nervous system.To further enhance the trial, the company plans to enroll 20 additional patients, focusing on those experiencing higher levels of pain.<figure class="image"><a href="https://stocktwits.com/symbol/AMIX"><img style="aspect-ratio:1285/291;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_103029_e257a3d1ef.png" alt="Screenshot 2024-10-28 103029.png" width="1285" height="291"></a><figcaption>Autonomix Medical's sentiment meter as of 10:30 a.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits shot up to ‘extremely bullish’ (89/100) from ‘neutral’ a day ago accompanied by ‘extremely high’ (92/100) chatter.&nbsp;On Thursday last week, Autonomix completed a 1-for-20 reverse stock split. Every 20 shares were combined into one share, reducing the total number of outstanding shares from about 23 million to around 1.15 million.Autonomix’s stock has been struggling since its listing in February, earlier this year. It saw highs of $152 and has since lost 86% of its value.For updates and corrections email newsroom@stocktwits.com.Read more:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/biontech-stock-falls-after-fda-concerns/cJ22FLsRIs">BioNTech Stock Dips On FDA Concerns Over Cancer Drug Trial: Retail Response Mixed</a>

Autonomix Medical reported positive preliminary results from its ongoing proof-of-concept human clinical trial. | Source: Pexels

Autonomix’s Stock Rallies on Strong Trial Results: Retail Sentiment Soars

Autonomix’s stock has been struggling since its listing in February, earlier this year. It saw highs of $152 and has since lost 86% of its value. Monday’s surge in share price comes after the company completed a 1-for-20 reverse stock split on Thursday.

This account has been verified as an official AMIX representative.

Verified Account

Autonomix Medical

Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies. The company was founded by Robert Schwartz, Landy Toth, David A. Robins, and Robert A. Van Tassel on June 10, 2014 and is headquartered in The Woodlands, TX.

Autonomix Medical Inc.

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

AMIX
Autonomix Medical Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest AMIX News

AMIXAutonomix Medical Inc.